| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | Chief Financial Officer | Common Shares | 488,656 | $1,607,678 | $3.29 | 06 Dec 2025 | Direct |
| Rubius Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 143,750 | 31 Jan 2022 | Direct | ||
| Rubius Therapeutics, Inc. | Chief Financial Officer | Restricted Stock Units | 34,500 | 31 Jan 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | 06 Dec 2025 | 1 | -$175,146 | 4 | Chief Financial Officer | 09 Dec 2025, 17:09 |
| ADCT | ADC Therapeutics SA | 13 Feb 2025 | 1 | +$386,400 | 4 | Chief Financial Officer | 14 Feb 2025, 18:21 |
| ADCT | ADC Therapeutics SA | 06 Dec 2024 | 1 | -$150,578 | 4 | Chief Financial Officer | 09 Dec 2024, 20:37 |
| ADCT | ADC Therapeutics SA | 02 Jan 2024 | 0 | $0 | 3 | Chief Financial Officer | 02 Jan 2024, 20:09 |
| /report/000117911022000696-carmona-jose-2022-01-31 | Rubius Therapeutics, Inc. | 31 Jan 2022 | 2 | $0 | 4 | Chief Financial Officer | 01 Feb 2022, 20:20 |